drugset / Trial / NCT06712173
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I, multicenter, non-randomized, open-label, dose-exploratory clinical study to evaluate the safety and tolerability of linperlisib combined with SHR2554 in the treatment of R/R PTCL, and to preliminary observe the antitumor efficacy of the combination of the two drugs.
Timeline
- Start
- 2024-12-01
- Primary completion
- 2025-09-30
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linperlisib | Small molecule | 40 mg | — |
| Subject | Linperlisib | Small molecule | 60 mg | — |
| Subject | SHR2554 | Small molecule | 150 mg | — |
| Subject | SHR2554 | Small molecule | 200 mg | — |
| Subject | SHR2554 | Small molecule | 300 mg | — |